Sangamo Therapeutics Reports Significant Drop in Revenue and EPS Miss for Q4
Wednesday, 13 March 2024, 14:02
Sangamo Therapeutics Q4 Performance
Sangamo Therapeutics reported disappointing Q4 results, missing the estimated GAAP EPS by $0.08 and experiencing a 92.5% decrease in revenue.
Key Points:
- EPS Miss: The GAAP EPS stood at -$0.34, missing by $0.08.
- Revenue Decline: Revenue amounted to $2.04M, missing by $6.07M.
This negative performance indicates challenges ahead for Sangamo Therapeutics.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.